Hookipa Pharma Inc

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its product includes VaxWace and TheraT. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, Katherine Cohen, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2021 financial results before the market opens on Thursday, March 24, 2022. The Company will host a live conference call and webcast at 8:30 AM ET to discuss its financial results and provide a corporate update.

HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate HOOKIPA Pharma Inc. (HOOK) to Report a Decline in Earnings: What to Look Out for

NEW YORK and VIENNA, Austria, March 08, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that preclinical, translational, and clinical biomarker data from its oncology pipeline have been selected for four poster presentations at the 2022 American Association for Cancer Research Annual Meeting (AACR), taking place April 8-13.

HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology

NEW YORK and VIENNA, Austria, March 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 21,700,000 shares of its common stock and 15,800 shares of its non-voting Series A-1 convertible preferred stock (the “Offering”). The public offering price of each share of common stock is $2.00 and the public offering price of each share of non-voting Series A-1 preferred stock is $2,000 (each share of non-voting Series A-1 preferred stock is convertible into 1,000 shares of common stock). HOOKIPA has granted the underwriters a 30-day option to purchase up to an additional 5,625,000 shares of its common stock at the public offering price of the common stock, less underwriting discounts and commissions. The gross proceeds to HOOKIPA from this offering are expected to be $75.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. All of the securities in the Offering are to be sold by HOOKIPA. The Offering is expected to close on March 4, 2022, subject to customary closing conditions.

HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

NEW YORK and VIENNA, Austria, March 01, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it intends to offer and sell shares of its common stock and shares of its non-voting Series A convertible preferred stock in an underwritten public offering (the “Offering”). HOOKIPA also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the Offering, including the shares of common stock underlying the non-voting Series A convertible preferred stock. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the size or terms of the offering. All of the securities in the Offering are to be sold by HOOKIPA.

HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

AppHarvest

MicroVision

BitNile Holdings

Ring Energy

Short squeeze stocks to watch right now. The post Best Penny Stocks To Buy Right Now?

Best Penny Stocks To Buy Right Now? 5 Short Squeeze Stocks To Watch

Blink Charging

Weber

Kaival Brands Innovations Group

MDJM Ltd

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch: Kaival Brands Cost To Borrow Hits Record 409%, Blink Charging And Weber Grills Move Up

Agriforce Growing Systems Ltd

Creative Medical Technology Holdings

Datasea Inc

loanDepot

Maris-Tech

Revelation Biosciences

vTv Therapeutics

Low float penny stocks to add to your watch list right now. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 8 Low Float Stocks To Watch Right Now

Vinco Ventures

Team

What you need to know about trading penny stocks on February 16th The post Trading Penny Stocks? Top Stock Market News for February 16th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for February 16th, 2022

Gilead Sciences

Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). In April 2018, Gilead licensed exclusive rights to Hookipa's arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV).

Hookipa Pharma Stock Surges On HIV Pact With Gilead

NEW YORK and VIENNA, Austria, Feb. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced it has entered into an amended and restated collaboration and license agreement with Gilead to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV).

HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV

NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference, February 14 - 18, 2022.

HOOKIPA to Present at the SVB Leerink Global Healthcare Conference

NEW YORK and VIENNA, Austria, Jan. 18, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the first patient has been dosed with HB-200 in combination with pembrolizumab for the treatment of 1st-line advanced/metastatic Human Papillomavirus 16 Positive (HPV16+) squamous cell head and neck cancers (HNSCC) in a Phase 2 arm of the ongoing Phase 1/2 trial (NCT04180215). In addition, the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the Company's novel immunotherapy candidates, single-vector HB-201 and alternating 2-vector HB-202/HB-201, both in combination with pembrolizumab, for the treatment of 1st-line advanced/metastatic HPV16+ HNSCC.

HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA's Fast Track Designation

NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company will present at the virtual H.C. Wainwright BioConnect Conference, January 10 - 13, 2022.   The presentation will be available beginning at 7:00 AM EST on Monday, January 10.

HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference

NEW YORK and VIENNA, Austria, Dec. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA's management team will participate in virtual investor meetings and present at The JMP Securities Hematology and Oncology Summit that will be held December 6-7, 2021.

HOOKIPA Pharma to Participate in the JMP Securities Hematology and Oncology Summit

NEW YORK and VIENNA, Austria, Nov. 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the third quarter of 2021.

HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights

NEW YORK and VIENNA, Austria, Nov. 09, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced it is advancing HB-201 to Phase 2, to be evaluated in combination with pembrolizumab as 1st- or 2nd-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC). Interim Phase 1 data in heavily pre-treated patients continue to show HB-200 monotherapy (both HB-201 alone and HB-202/HB-201) is highly effective at expanding T cells, has a favorable tolerability profile and promising, early anti-tumor activity. As of November 1, 2021, among 28 patients dosed intravenously, HB-200 resulted in a 75 percent disease control rate and shrinkage of target lesions in 53 percent of patients. In these patients, HOOKIPA has observed three partial responses (including one confirmed and one unconfirmed in an ongoing patient) and one ongoing patient with a near partial response (29 percent tumor shrinkage). Based on the strength of the HB-200 data, HOOKIPA has prioritized its oncology portfolio and plans further development of its infectious disease programs to be done in partnership with other companies. HOOKIPA will host an investor conference call to review the data at 4:30 p.m. ET.

HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform

HOOKIPA Pharma (NASDAQ:HOOK) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.

Preview: HOOKIPA Pharma's Earnings

Earnings Preview: HOOKIPA Pharma Inc. (HOOK) Q3 Earnings Expected to Decline

NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release third quarter 2021 financial results before the market opens on Wednesday, November 10, 2021.

HOOKIPA Pharma to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

NEW YORK and VIENNA, Austria., Oct. 14, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the publication of a comprehensive review article on arenaviral immunotherapies in the peer-reviewed online journal, Frontiers in Oncology (Link). The article reinforces the potential of HOOKIPA's versatile arenavirus platform as a promising strategy to elicit potent, tumor-specific T cell responses and help address critical unmet needs in the treatment of cancer.

HOOKIPA announces publication on the benefits of its novel arenaviral immunotherapeutics in cancer in Frontiers in Oncology

Merck

HOOKIPA (HOOK) collaborates with Merck (MRK) to evaluate the combination of its immunotherapy program, HB-200, with Merck's Keytruda for advanced head and neck squamous cell carcinoma.

HOOKIPA (HOOK), Merck Collaborate to Treat Head & Neck Cancers

Hookipa Pharma Inc (NASDAQ: HOOK) has entered into a clinical collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The collaboration will evaluate the combination of HB-200 and Keytruda (pembrolizumab) as first-line treatment of advanced head and neck squamous cell carcinoma (HNSCC).

Hookipa Pharma, Merck Team Up For Phase 2 Head & Neck Cancer Trial

NEW YORK and VIENNA, Austria, Sept. 15, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced it has entered into a clinical collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ., USA (known as MSD outside of the United States and Canada) to evaluate the combination of HB-200, a novel arenaviral immunotherapeutic, and Merck & Co., Inc., Kenilworth, NJ., USA's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) as first-line treatment for patients with advanced head and neck squamous cell carcinoma (HNSCC).

HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers

Shares of HOOKIPA Pharma (NASDAQ:HOOK) moved higher by 3.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 85.71% over the past year to ($0.52), which beat the estimate of ($0.53).

Recap: HOOKIPA Pharma Q2 Earnings

News for Hookipa Pharma Inc Stock (HOOK)